PXL065
Clinical data
Other namesDRX-065; Deuteropioglitazone; (R)-Deuteropioglitazone
Identifiers
  • (5R)-5-Deuterio-5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC19H20N2O3S
Molar mass356.44 g·mol−1
3D model (JSmol)
  • [2H][C@]1(C(=O)NC(=O)S1)CC2=CC=C(C=C2)OCCC3=NC=C(C=C3)CC
  • InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)/t17-/m1/s1/i17D
  • Key:HYAFETHFCAUJAY-VHLRUQIKSA-N

PXL065 (deuteropioglitazone) is an experimental drug for the treatment of nonalcoholic steatohepatitis (NASH).[1][2] It is a deuterated derivative of the (R)-enantiomer of pioglitazone that is designed to have a better safety profile than pioglitazone itself.[1]

References

  1. 1 2 Harrison, Stephen A.; Thang, Carole; Bolze, Sébastien; Dewitt, Sheila; Hallakou-Bozec, Sophie; Dubourg, Julie; Bedossa, Pierre; Cusi, Kenneth; Ratziu, Vlad; Grouin, Jean-Marie; Moller, David E.; Fouqueray, Pascale (2023). "Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)". Journal of Hepatology. 78 (5): 914–925. doi:10.1016/j.jhep.2023.02.004. PMID 36804402. S2CID 257034807.
  2. ↑ Monternier, Pierre-Axel; Singh, Jaspreet; Parasar, Parveen; Theurey, Pierre; Dewitt, Sheila; Jacques, Vincent; Klett, Eric; Kaur, Navtej; Nagaraja, Tavarekere N.; Moller, David E.; Hallakou-Bozec, Sophie (2022). "Therapeutic potential of deuterium-stabilized ( R )-pioglitazone—<SCP>PXL065</SCP>—for X-linked adrenoleukodystrophy". Journal of Inherited Metabolic Disease. 45 (4): 832–847. doi:10.1002/jimd.12510. PMC 9545763. PMID 35510808.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.